Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has announced its upcoming participation in the Stifel 2025 Virtual Targeted Oncology Forum. CEO Michael A. Metzger and other management team members will engage in a fireside chat scheduled for Wednesday, April 9, 2025, at 10:30 a.m. ET. The event will be accessible via live webcast through the company's website investor section, with a replay option available for a time.
Syndax Pharmaceuticals (Nasdaq: SNDX), una compagnia biofarmaceutica in fase commerciale focalizzata sulle terapie per il cancro, ha annunciato la sua prossima partecipazione al Stifel 2025 Virtual Targeted Oncology Forum. Il CEO Michael A. Metzger e altri membri del team dirigenziale parteciperanno a una chiacchierata informale programmata per mercoledì 9 aprile 2025, alle 10:30 a.m. ET. L'evento sarà accessibile tramite webcast dal vivo attraverso la sezione investitori del sito web della compagnia, con un'opzione di replay disponibile per un certo periodo di tempo.
Syndax Pharmaceuticals (Nasdaq: SNDX), una empresa biofarmacéutica en etapa comercial centrada en terapias contra el cáncer, ha anunciado su próxima participación en el Stifel 2025 Virtual Targeted Oncology Forum. El CEO Michael A. Metzger y otros miembros del equipo directivo participarán en una charla informal programada para miércoles 9 de abril de 2025, a las 10:30 a.m. ET. El evento será accesible a través de una transmisión en vivo a través de la sección de inversores del sitio web de la empresa, con una opción de repetición disponible por un tiempo determinado.
신닥스 제약(Syndax Pharmaceuticals) (Nasdaq: SNDX)는 암 치료에 중점을 둔 상업 단계의 생명공학 회사로, 스티펠 2025 가상 표적 종양학 포럼(Stifel 2025 Virtual Targeted Oncology Forum)에 참여할 예정이라고 발표했습니다. CEO 마이클 A. 메츠거(Michael A. Metzger)와 기타 경영진이 2025년 4월 9일 수요일 오전 10시 30분 ET에 예정된 대화에 참여할 것입니다. 이 행사는 회사 웹사이트의 투자자 섹션을 통해 실시간 웹캐스트로 접근 가능하며, 일정 기간 동안 다시 볼 수 있는 옵션도 제공됩니다.
Syndax Pharmaceuticals (Nasdaq: SNDX), une société biopharmaceutique en phase commerciale axée sur les thérapies contre le cancer, a annoncé sa prochaine participation au Stifel 2025 Virtual Targeted Oncology Forum. Le PDG Michael A. Metzger et d'autres membres de l'équipe de direction participeront à une discussion informelle prévue pour mercredi 9 avril 2025, à 10h30 ET. L'événement sera accessible via un webinaire en direct sur la section investisseurs du site Web de l'entreprise, avec une option de rediffusion disponible pendant un certain temps.
Syndax Pharmaceuticals (Nasdaq: SNDX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Krebstherapien konzentriert, hat seine bevorstehende Teilnahme am Stifel 2025 Virtual Targeted Oncology Forum bekannt gegeben. CEO Michael A. Metzger und andere Mitglieder des Management-Teams werden an einem informellen Gespräch teilnehmen, das für Mittwoch, den 9. April 2025, um 10:30 Uhr ET geplant ist. Die Veranstaltung wird über einen Live-Webcast über den Investorenbereich der Unternehmenswebsite zugänglich sein, mit einer Wiederholungsoption für einen bestimmten Zeitraum.
- None.
- None.
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET.
A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
When is Syndax Pharmaceuticals (SNDX) presenting at the Stifel 2025 Virtual Targeted Oncology Forum?
Who will represent SNDX at the Stifel 2025 Virtual Oncology Forum?
How can investors watch SNDX's presentation at the Stifel 2025 Forum?
What type of company is SNDX and what is their focus?
